Management of the transplant recipient with chronic hepatitis C.

Abstract

More than one-third of listed potential liver recipients in the US are infected with the hepatitis C virus (HCV). Recurrence of infection with HCV after liver transplantation is associated with accelerated graft loss and diminished patient survival. Current HCV treatments using peginterferon and ribavirin either alone or with first generation protease inhibitors (telaprevir, boceprevir) are limited by suboptimal viral response, drug-drug interaction, and side effects, some of which may be graft- or life-threatening. Rapid advances in new drug therapy for HCV promise to improve outcomes, reduce side effects and drug-drug interaction, shorten treatment duration, and simplify treatment regimens.

• Authors: James R Burton Jr, Gregory T Everson
• Journal: Clinics in liver disease (Clin Liver Dis) Vol. 17 Issue 1 Pg. 73-91 (Feb 2013) ISSN: 1557-8224 [Electronic] United States
• PMID: 23177284 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2013. Published by Elsevier Inc.

Chemical References

• Antiviral Agents
• Immunosuppressive Agents
• Oligopeptides
• Serine Proteinase Inhibitors
• Polyethylene Glycols
• Ribavirin
• telaprevir
• N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
• Interferons
• Proline

Topics

• Antiviral Agents (therapeutic use)
• Drug Therapy, Combination (adverse effects)
• Hepatitis C, Chronic (drug therapy)
• Humans
• Immunocompromised Host
• Immunosuppressive Agents (therapeutic use)
• Interferons (therapeutic use)
• Liver Transplantation
• Oligopeptides (therapeutic use)
• Polyethylene Glycols (therapeutic use)
• Postoperative Care
• Preoperative Care
• Proline (analogs & derivatives, therapeutic use)
• Ribavirin (therapeutic use)
• Serine Proteinase Inhibitors (therapeutic use)